SpringerLink
Log in

Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (青黄散) in Patients with Myelodysplastic Syndrome

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the relation of blood arsenic concentration (BAC) with clinical effect and safety of arsenic-containing Qinghuang Powder (青黄散, QHP) in patients with myelodysplastic syndrome (MDS).

Methods

Totally 163 patients with MDS were orally treated with QHP for 2 courses of treatment, 3 months as 1 course. The BACs of patients were detected by atomic fluorescence spectrophotometry at 1, 3, and 6 months during the treatment, and the effective rate, hematological improvement and safety in patients after treatment with QHP were analyzed.

Results

After 2 courses of treatment, the total effective rate was 89.6% (146/163), with 31.3% (51/163) of hematological improvement and 58.3% (95/163) of stable disease. The hemoglobin increased from 73.48 ± 19.30 g/L to 80.39 ± 26.56 g/L (P<0.05), the absolute neutrophil count increased from 0.81 ± 0.48 × 109/L to 1.08 ± 0.62 × 109/L (P<0.05), and no significant changes were observed in platelet counts (P>0.05). Among 46 patients previously depended on blood transfusion, 28.3% (13/46) completely got rid of blood transfusion and 21.7% (10/46) reduced the volume of blood transfusion by more than 50% after treatment. The BACs were significantly increased in patients treated for 1 month with 32.17 ± 18.04 μ g/L (P<0.05), 3 months with 33.56 ± 15.28 μ g/L (P<0.05), and 6 months with 36.78 ± 11.92 μ g/L (P<0.05), respectively, as compared with those before treatment (4.08 ± 2.11 μ g/L). There were no significant differences of BACs among the patients treated for 1, 3 and 6 months (P>0.05). The adverse reactions of digestive tract during the treatment were mild abdominal pain and diarrhea in 14 cases (8.6%), and no patients discontinued the treatment. The BACs of patients with gastrointestinal adverse reactions were significantly lower than those without gastrointestinal adverse reactions (22.39 ± 10.38 vs. 37.89 ± 11.84, μ g/L, P<0.05). The BACs of patients with clinical effect were significantly higher than those failed to treatment (40.41 ± 11.69 vs. 23.84 ± 12.03, μ g/L, P<0.05).

Conclusion

QHP was effective and safe in the treatment of patients with MDS and the effect was associated with BACs of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:831–841.

    Article  PubMed  Google Scholar 

  2. Hu XM, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 2010;16:368–377.

    Article  CAS  PubMed  Google Scholar 

  3. Xu S, Ma R, Hu XM, Xu YG, Yang XH, Wang HZ, et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. Chin J Integr Med 2011;17:834–839.

    Article  PubMed  Google Scholar 

  4. Sun SZ, Ma R, Hu XM, Yang XH, Xu YG, Wang HZ, et al. Karyotype and DNA-methylation responses in myelodysplastic syndromes following treatment with traditional Chinese formula containing arsenic. Evid Based Complement Alternat Med 2012;969476. doi: https://doi.org/10.1155/2012/969476.

    Google Scholar 

  5. Ma JL, Qu WW, Hu XM. Correlationship of clonal selection of treatment with arsenious compound formula Qinghuang Powder with in vivo effects of arsenic in patients with myelodysplastic syndrome. Chin J Inform Tradit Chin Med (Chin) 2013;20:8–10.

    Google Scholar 

  6. Valent P, Horny H, Bennett J M, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leukemia Res 2007;31:727–736.

    Article  Google Scholar 

  7. Swerdlow SH, Campo E, Harris NL, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC;2008:88–93.

    Google Scholar 

  8. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWGMRT). Blood 2006;108:1497–1503.

    Article  CAS  PubMed  Google Scholar 

  10. Zheng XY, ed. Guidelines for the clinical research of new traditional Chinese medicine (Trial). Bei**g: China Medical Science and Technology Press; 2002:19–20.

    Google Scholar 

  11. Wang Y, Fang S, Song MM, Hu XM. Safety of Compound Qinghuang Powder in patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2014;36:1074–1077.

    CAS  Google Scholar 

  12. Wang Y, Fang S, Deng ZY, Song MM, Ma JL, Yang XP, et al. Compound Qinghuang Powder in the treatment of patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2015;37:1091–1095.

    Google Scholar 

  13. Hu XM, Tanaka S, Onda K, Yuan B, Toyoda H, Ma R, et al. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. Chin J Integr Med 2014;20:387–393.

    Article  CAS  PubMed  Google Scholar 

  14. Hu XM, Yuan B, Tanaka S, Song MM, Onda K, Tohyama K, et al. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. Hematology 2014;19:352–360.

    Article  CAS  PubMed  Google Scholar 

  15. Hu XM, Yuan B, Song MM, Onda K, Tanaka S, Toyoda H, et al. Dose-dependent biphasic effects of arsenic disulfide on differentiation and apoptosis of HL-60 cells. Curr Topics Pharmacol 2014;17:13–25.

    Google Scholar 

  16. Hu XM, Yuan B, Tanaka S, Zhou QB, Onda K, Toyoda H, et al. Involvement of oxidative stress associated with glutathione depletion and p38 MAPK activation in arsenic disulfide-induced differentiation in HL-60 cells. Leuk Lymphom 2014;55:392–404.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, **yuan Hospital, China Academy of Chinese Medical Sciences, Bei**g, 100091, China

    Zhong-yang Deng, Shi-rong Zhu, Ming-**g Wang, Pan Zhao, Qian-zhe Zhu, Hong-zhi Wang, **ao-qing Guo, Yong-gang Xu, Bo-wen Yi, **ao-hong Shang, Rou Ma & **ao-mei Hu

  2. Graduate School of China Academy of Chinese Medical Sciences, Bei**g, 100700, China

    Zhong-yang Deng, Ming-**g Wang, Pan Zhao & Qian-zhe Zhu

  3. Graduate School of Bei**g University of Chinese Medicine, Bei**g, 100000, China

    Shi-rong Zhu

  4. Zhengyuan Clinic of Nantong, Nantong, 226000, Jiangsu Province, China

    Su Fang

Authors
  1. Zhong-yang Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shi-rong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming-**g Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Su Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qian-zhe Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hong-zhi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. **ao-qing Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yong-gang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bo-wen Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. **ao-hong Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rou Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. **ao-mei Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to **ao-mei Hu.

Additional information

Supported by Bei**g Municiple Science and Technology Commission (No. Z141100006014003), National Natural Science Foundation of China (No. 81673821), and Special Research Foundation of Central Level Public Scientific Research Institutes (No. ZZ10-016)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deng, Zy., Zhu, Sr., Wang, Mj. et al. Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (青黄散) in Patients with Myelodysplastic Syndrome. Chin. J. Integr. Med. 25, 497–501 (2019). https://doi.org/10.1007/s11655-019-3070-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-019-3070-2

Keywords

Search

Navigation